"Oxazolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.
| Descriptor ID |
D023303
|
| MeSH Number(s) |
D03.383.129.462.600
|
| Concept/Terms |
Oxazolidin-2-one- Oxazolidin-2-one
- Oxazolidin 2 one
- 2-oxazolidinone
- 2 oxazolidinone
- 2-Oxazolidone
- 2 Oxazolidone
- 1,3-Oxazolidin-2-one
- 1,3 Oxazolidin 2 one
- 1,3-Oxazolidine-2-one
- 1,3 Oxazolidine 2 one
|
Below are MeSH descriptors whose meaning is more general than "Oxazolidinones".
Below are MeSH descriptors whose meaning is more specific than "Oxazolidinones".
This graph shows the total number of publications written about "Oxazolidinones" by people in this website by year, and whether "Oxazolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazolidinones" by people in Profiles.
-
Nahas SJ, Hindiyeh N, Friedman DI, Elbuluk N, Kellerman DJ, Foreman PK, Schmidt P. Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine. J Headache Pain. 2021 May 17; 22(1):37.
-
Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache. 2019 04; 59(4):509-517.
-
Dodick DW, Tepper SJ, Friedman DI, Gelfand AA, Kellerman DJ, Schmidt PC. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial. Headache. 2018 Jul; 58(7):986-992.
-
Spierings EL, Brandes JL, Kudrow DB, Weintraub J, Schmidt PC, Kellerman DJ, Tepper SJ. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia. 2018 02; 38(2):215-224.
-
Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep; 53 Suppl 2:62-71.
-
Podos SD, Thanassi JA, Leggio M, Pucci MJ. Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci. Antimicrob Agents Chemother. 2012 Jul; 56(7):3812-8.
-
Ji C, Lin W, Moraski GC, Thanassi JA, Pucci MJ, Franzblau SG, Möllmann U, Miller MJ. Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction. Bioorg Med Chem. 2012 Jun 1; 20(11):3422-8.
-
Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache. 2011 Jan; 51(1):64-72.
-
George JM, Fiscella R, Blair M, Rodvold K, Ulanski L, Stokes J, Blair N, Pontiggia L. Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. J Ocul Pharmacol Ther. 2010 Dec; 26(6):579-86.
-
Dodick DW, Kost J, Assaid C, Lines C, Ho TW. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia. 2011 Feb; 31(3):296-300.